Introducing BacoMind®
BacoMind® from Bacopa monnieri is a patented, clinically tested, full-spectrum extract of nine bioactive compounds to support memory and cognitive abilities for children and adults.
BacoMind® is the only brand of Bacopa monnieri with nine different bioactives providing a holistic targeted benefit — bacopasaponin C, bacopaside I, bacopaside II, bacoside A3, beta-sitosterol-D-glucoside, jujubogenin isomer of bacopasaponin C, bacosine, apigenin and luteolin. It is also the first Bacopa to be GRAS.
BacoMind®: 9 unique bioactives
Traditional uses 
Bacopa monnieri has been relied upon in India by Ayurvedic medical practitioners for nearly 3,000 years. Ayurvedic practitioners have classified Bacopa as a ‘medhyarasayana’, a treatment for improving memory and intellect (‘medhya’). Additionally, the herb has been mentioned in several ancient Ayurvedic treatises including the Charaka Samhita (6th century AD) and, about 1,000 years later, the Bravprakash Var-Prakarana (16th century AD).
As Brahmi, Bacopa has been utilized in traditional Ayurveda as a nerve tonic to improve learning, memory, and concentration, as well as to relieve anxiety and support against epileptic disorders.
Brahmi is said to balance both brain hemispheres as well as to stimulate awakening of the crown chakra Sahastrara, the seventh spiritual chakra at the top of the head.
BacoMind® clinical research
BacoMind® is clinically researched to support cognitive performance with four human efficacy clinical trials — two in elderly populations, two in children, and one safety human study.

Clinical Study 1
BacoMind® improved memory acquisition and retention
Clinical Study 2
BacoMind® improved verbal memory
Clinical Study 3
Children requiring IEP showed improvement in the battery of memory tests.
Clinical Study 4
BacoMind® significantly (p<0.05) reduced 6 out of 7 symptoms of ADHD in all children
Clinical Study 5
BacoMind® was found to be safe for human consumption
A randomized double blind placebo controlled study in elderly Australians for memory
Morgan and Stevens.The Journal of Alternative and Complimentary Medicine 2010, 16 : 753-759
Know More
Effect of BacoMind® in elderlies
A randomized double blind placebo-controlled study in elderly Indians for memory
Barbhaiya et al. Journal of Pharmacology and Toxicology 2008, 3: 425-434
Know More
Effect of BacoMind® in elderlies
An open labeled clinical study in children requiring IEP
Usha et al. Journal of Pharmacology and Toxicology 2008, 3(4): 302-310
Know More
Effects of BacoMind® in children requiring IEP
Open labeled study in children with ADHD
Dave et al. Advances in Mind-Body Medicine 2014, 28(2):10-5
Know More
Effects of BacoMind® in children with ADHD
A randomized, open label, dose escalation safety study in healthy adults
Bacomind® pre-clinical research
Preliminary research in rats and mice have demonstrated that both an aqueous decoction and alcoholic extract enhanced learning ability in rats, as well as facilitated cognitive function and mental retention capacity.
These studies informed the objective of a pre-clinical study evaluating the nootropic activity of BacoMind® in different learning and memory paradigms such as elevated plus maze, passive shock avoidance test, and object recognition test. BacoMind® was administered for 7 days to mice in an elevated plus maze and passive shock avoidance test, and to rats in object recognition test. Scopolamine was used to induce forgetfulness (amnesia) and piracetam served as a reference standard.
Results were highly encouraging, demonstrating that BacoMind® has strong nootropic activity. In the elevated plus maze test, BacoMind® significantly increased the inflexion ratio in scopolamine treated mice. In passive shock avoidance test, BacoMind® significantly reduced the latency to reach the shock free zone and number of mistakes in 15 minutes in both normal as well as scopolamine treated mice. In object recognition test, BacoMind® significantly increased the discrimination index in both normal as well as scopolamine treated rats.
Reference: Kasture et al.. Journal of Natural Remedies 2007, 7(1): 166-173
BacoMind®: Unique mechanism of action

BacoMind®– Only Bacopa with human safety study
The subjective and objective evaluation of BacoMind® in healthy adult volunteers revealed that, at the given oral dose of 300 mg once a day for first 15 days and 450 mg once a day for next 15 days, the herbal supplement was found to be safe and tolerable.

Dosage*
Adults: 300 to 450 mg per day
Children: 225 mg per day
Health Benefits
Supports learning and memory in adults*
Supports learning and memory in children (Age >4 years)*
Supports memory acquisition and retention in elderly*
Supports verbal memory in elderly*
Helps manage the symptoms of ADHD in children (Age >6 years)*

BacoMind®– Only Bacopa extract with GRAS
The first brand of Bacopa extract to receive GRAS status — can be used as a food ingredient in beverages, candies (including gummies, chews, etc), and bakery products (including protein and breakfast bars) at levels of 50 mg per serving.
BacoMind®: Stands for the things that matter to you
Why choose BacoMind®?
World’s best Bacopa

Learn More
*Disclaimer:This website may contain statements and classification about product(s), which may not be in line with the regulations of your country. The statement or claims made are in reference to the ingredient only and therefore do not refer to any finished product directly or indirectly. The claims on the finished product containing our ingredient are the sole responsibility of manufacturer or the marketer. We urge manufacturer and marketer to ensure that the claims made on the finished product comply with the law and regulation of the country in which the product is to be sold. Statements used in this website have not been evaluated by FDA. The ingredient mentioned here is not intended to diagnose, treat, cure or prevent any disease.